做爰xxxⅹ性生交,色屁屁影院免费观看,亚洲午夜高清国产拍在线观看,亲嘴揉胸口激烈视频,中文字幕在线有码观看,激情大尺度同志小说,波多野结衣博客,与亲女洗澡时伦了2次,国产三级在线一区二区

您好，歡迎來到上海士研管理咨詢有限公司
產(chǎn)業(yè)峰會 演講局 專家智庫服務(wù) 峰會活動服務(wù) 整合營銷服務(wù)
  • 產(chǎn)業(yè)峰會：
    以專業(yè)團(tuán)隊對產(chǎn)業(yè)和市場客觀詳實地調(diào)研為前提，擁有戰(zhàn)略性、系統(tǒng)性、全球性的基因，匯集了領(lǐng)導(dǎo)者關(guān)注的熱點話題與領(lǐng)袖代表，為您提供“一站式”的對話、分享、社交平臺!
  • 演講局：
    致力于為全球企業(yè)和機(jī)構(gòu)提供主題演講家、高管大師班、董事會顧問，每項服務(wù)都提供了一種更深入、更具互動性的體驗，尤其是針對較小的精選受眾和關(guān)鍵個人。我們擁有最具影響力的商業(yè)領(lǐng)袖和頂級專家的資源，他們是各自領(lǐng)域的最杰出的代表。我們的團(tuán)隊由經(jīng)驗豐富的演講和活動經(jīng)理組成，我們注重建立長期而深入的伙伴關(guān)系。
  • 專家智庫服務(wù)：
    中國領(lǐng)先的行業(yè)專家知識信息服務(wù)供應(yīng)商，為需要專業(yè)洞見的商業(yè)決策者匹配具有一手經(jīng)驗的行業(yè)專家，助力他們以更加明確的目標(biāo)和堅定的信心做出決策。我們有60萬余名專家顧問遍布二十多個行業(yè)，而且每天還在增加！
  • 峰會活動服務(wù)：
    致力于成為全球最專業(yè)的產(chǎn)業(yè)峰會活動提供商，為企業(yè)和機(jī)構(gòu)的產(chǎn)業(yè)性峰會活動提供一站式專業(yè)服務(wù)，包括調(diào)研策劃、定制邀請、營銷推廣、運(yùn)營組織、項目管理、直播與數(shù)字化會議等，每項服務(wù)都由經(jīng)驗豐富的專業(yè)團(tuán)隊匹配長期沉淀的產(chǎn)業(yè)資源予以卓越執(zhí)行，我們注重建立長期而深入的伙伴關(guān)系。
  • 整合營銷服務(wù)：
    致力于成為全球領(lǐng)先的2B營銷服務(wù)機(jī)構(gòu)，聚焦產(chǎn)業(yè)高端活動、內(nèi)容、渠道的建設(shè)與沉淀，為客戶提供一站式整合營銷解決方案，助力企業(yè)線上線下獲客與品牌筑造。我們深信專業(yè)團(tuán)隊匹配產(chǎn)業(yè)資源帶來卓越執(zhí)行，我們注重建立長期而深入的伙伴關(guān)系。
嘉賓信息
發(fā)布時間: 2023 - 06 - 25
點擊次數(shù): 0
所屬職位： 首席執(zhí)行官
所屬公司： 邦耀生物
個人簡介：
鄭彪博士畢業(yè)于浙江大學(xué)醫(yī)學(xué)院醫(yī)學(xué)系；獲上海復(fù)旦大學(xué)醫(yī)學(xué)院免疫學(xué)碩士及倫敦大學(xué) (King’s College, University of London) 免疫學(xué)博士學(xué)位。曾在美國馬里蘭大學(xué)醫(yī)學(xué)院 (University of Maryland School of Medicine) 及杜克大學(xué)醫(yī)學(xué)中心 (Duke University Medical Center) 任教。隨后任職于美國貝勒醫(yī)學(xué)院 (Baylor College of Medicine), 為該校病理和免疫系終身教授。在葛蘭索史克 (GlaxoSmithKline) 研發(fā)中心負(fù)責(zé)免疫學(xué)研究工作。曾任美國強(qiáng)生公司(Janssen Pharmaceuticals, Johnson & Johnson) 全球副總裁, 負(fù)責(zé)亞太地區(qū)免疫領(lǐng)域創(chuàng)新藥物研發(fā)，包括免疫調(diào)節(jié)機(jī)制、腫瘤免疫、及自身免疫性疾病。鄭彪博士現(xiàn)任邦耀生物首席執(zhí)行官。鄭彪教授學(xué)術(shù)著作豐厚，其中多篇發(fā)表在Nature和Science等世界頂尖雜志上。在馬里蘭大學(xué)、杜克大學(xué)及貝勒醫(yī)學(xué)院工作期間獲得多項重大科研基金，包括美國NIH科研基金、白血病與淋巴瘤協(xié)會基金、美國關(guān)節(jié)炎基金會、美國心臟研究協(xié)會基金、美國衰老研究聯(lián)盟基金等。在藥物研發(fā)方面，從新藥篩選、靶點研究、疾病模型、臨床前及臨床試驗等方面積累了重要的經(jīng)驗，對新藥開發(fā)全過程有深刻的認(rèn)識。在打造小分子藥，大分子抗體藥，細(xì)胞治療管線均有豐富的經(jīng)驗。Dr. Biao Zheng graduated with a medical degree from Zhejiang University School of Medicine. He received his PhD in Immunology from King’s College, University of London. Dr. Zheng served at the faculty of University of Maryland School of Medicine and Duke University Medical Center. He was a tenured professor in the Department of Pathology and Immunology, Baylor College of Medicine. Dr. Zheng worked for GlaxoSmithKline R&D Center as the head of Immunological Discovery Sciences. He was a global vice president of the Immunology Therapeutic Area, Janssen Pharmaceuticals, and Johnson & Johnson Innovation Center, Asia Pacific, responsible for the innovative immunological drug pipeline in the region. Dr. Zheng is now the Chief Executive Officer at BRL Medicine.Dr. Zheng is an experienced physician scientist, drug hunter, and professor with a demonstrated history working both in academia and pharmaceutical industry. He has more than thirty years of experience in biomedical research and drug discovery. He has published extensively in world top journals including Nature and Science. His major areas of research and development include autoimmune diseases, immuno-oncology, and novel vaccine development.
發(fā)布時間: 2023 - 06 - 25
點擊次數(shù): 0
所屬職位： 副總裁
所屬公司： 蘇州開拓藥業(yè)
個人簡介：
許若博士本科就讀于北京大學(xué)化學(xué)系，之后獲美國哥倫比亞大學(xué)博士學(xué)位。從1998年開始，許博士先后在先靈堡雅、默克、API Inc.等美國大小制藥企業(yè)的工作20多年，在藥物化學(xué)，工藝化學(xué)，原料藥的cGMP制造，CMC文件準(zhǔn)備和提交等領(lǐng)域積累了豐富的經(jīng)驗。許博士于2019年4月回國加入開拓藥業(yè)股份有限公司，擔(dān)任化學(xué)副總裁職務(wù)。全面負(fù)責(zé)公司的藥物化學(xué)的研發(fā)和原料藥的生產(chǎn)工作。Dr. Xu received his bachelor's degree in chemistry from Peking University and his Ph.D. from Columbia University. After his academic training, Dr. Xu has worked in pharmaceutical industry for more than 20 years, including Schering-Plough, Merck, API Inc. etc. in the United States. During this time, he accumulated rich experience in medicinal chemistry, process chemistry, cGMP manufacturing of APIs, CMC document preparation and submission, etc. Dr. Xu returned to China in April 2019 and joined Kintor Pharma as Vice President of Chemistry. He is responsible for the medicinal chemistry research and the production of APIs of the company.
發(fā)布時間: 2023 - 06 - 25
點擊次數(shù): 0
所屬職位： 創(chuàng)始人、董事長兼總經(jīng)理
所屬公司： 宜明昂科生物醫(yī)藥技術(shù)（上海）股份有限公司
個人簡介：
田文志博士，上海市“千人計劃”專家、浦東新區(qū)“百人計劃”專家、科技部火炬中心科技創(chuàng)新創(chuàng)業(yè)人才、復(fù)旦大學(xué)藥學(xué)院兼職教授，現(xiàn)任宜明昂科生物醫(yī)藥技術(shù)（上海）股份有限公司董事長兼總經(jīng)理。于1995年10月至2011年4月先后在瑞典、美國留學(xué)及工作，主要從事腫瘤免疫學(xué)及抗腫瘤抗體藥物開發(fā)研究。累計發(fā)表學(xué)術(shù)論文30余篇，克隆新基因7個，參編英文專著一部，申請新藥發(fā)明專利40余項，獲得授權(quán)13項。2011年4月辭職回國，先后創(chuàng)辦了華博生物醫(yī)藥技術(shù)（上海）有限公司、宜明昂科生物醫(yī)藥技術(shù)（上海）股份有限公司及宜明探科生物醫(yī)藥技術(shù)（上海）有限公司?；貒?2年以來，已將 8個新藥項目開發(fā)至臨床試驗階段，其中7項已開展臨床試驗。Dr. Wenzhi Tian is the founder and Chairman of IImmuneOnco Biopharmaceuticals (Shanghai) Inc., a clinical stage biotech company headquartered in Shanghai, China, with primary focus on research and development of tumor immunotherapeutic drugs including checkpoint modulators and target-activated NK (TANKTM) products. Prior to ImmuneOnco Biopharma, Dr. Tian worked as Chief Executive Officer at Huabo Biopharm from June of 2011 to April of 2015. During that period, Dr. Tian advanced two large molecule programs to the clinical stage. Prior to moving back to China, Dr. Tian worked as Principal Research Scientist at ImClone Systems from January of 2006 to April of 2011. Dr. Tian graduated from Henan Medical University (Now Zhengzhou University School of Medicine) and did his postdoctoral training at North Shore University Hospital, NYU School of Medicine. He was appointed a Senior Research Associate at Weill Medical College of Cornell University thereafter.
發(fā)布時間: 2023 - 06 - 25
點擊次數(shù): 0
所屬職位： 執(zhí)行董事、首席執(zhí)行官
所屬公司： 蘇州創(chuàng)勝醫(yī)藥集團(tuán)有限公司
個人簡介：
錢雪明博士是創(chuàng)勝集團(tuán)醫(yī)藥有限公司（下稱創(chuàng)勝集團(tuán)）的首席執(zhí)行官。創(chuàng)勝集團(tuán)是一家具備生物藥發(fā)現(xiàn)、研發(fā)、工藝開發(fā)和生產(chǎn)全流程整合能力的臨床階段的生物制藥公司。2021年9月29日，創(chuàng)勝集團(tuán)在香港聯(lián)合交易所主板上市，股票代碼：06628。錢雪明博士畢業(yè)于復(fù)旦大學(xué)生物物理學(xué)系 (1985 – 1990)，并分別在哥倫比亞大學(xué) (Columbia University, 1990 – 1992) 和奧爾巴尼醫(yī)學(xué)中心 (Albany Medical Center, 1995 – 1997) 獲得神經(jīng)學(xué)與生理學(xué)碩士學(xué)位和神經(jīng)學(xué)與藥理學(xué)博士學(xué)位。錢雪明博士擁有 20 年的生物制藥行業(yè)經(jīng)驗。在創(chuàng)立創(chuàng)勝集團(tuán)之前，錢博士于 2010-2013 年間任盛諾基醫(yī)藥集團(tuán) (Shenogen Pharma Group) 研發(fā)總裁和董事會成員。1997-2010 間任職于美國安進(jìn)公司，專注于抗體新藥的開發(fā)。錢博士是十多個創(chuàng)新藥物專利申請的發(fā)明人，也是國際抗體協(xié)會會員、國際腎病協(xié)會會員、新藥創(chuàng)始人俱樂部、創(chuàng)新生物社和 BayHelix 百華協(xié)會會員，獲得了國家級高層次人才、蘇州工業(yè)園區(qū)科技領(lǐng)軍人才和蘇州市姑蘇創(chuàng)新創(chuàng)業(yè)領(lǐng)軍人才等支持。Dr. Xueming Qian is the CEO of Transcenta Holding Limited (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics. Dr. Qian received his B.S. in Biophysics from Fudan University (Shanghai, China, 1985 – 1990), M.A. in Neuroscience/Physiology from Columbia University (New York, USA, 1990 – 1992) and Ph.D. in Neuroscience and Pharmacology from Albany Medical Center (New York, USA, 1995 – 1997).Dr. Qian has over twenty years of industrial experience in biotechnology drug discovery and development. Before starting Transcenta, Dr. Qian was Senior VP and R&D Head of Shenogen Pharma Group from 2010 and 2013. Dr. Qian worked more than 12 years at Amgen as principal scientist and project team leader from 1997 and 2010. Dr. Qian is the author over ten patent applications and a member of the New Drug Founder’s Club, Bio-logics Innovation Group, BayHelix as well as several scientific organizations such as ASCO, ESMO, AACR, ASN and Antibody Society.
微信公眾號
領(lǐng)導(dǎo)者網(wǎng)絡(luò)APP
Copyright ?2005 - 2017上海士研管理咨詢有限公司
犀牛云提供企業(yè)云服務(wù)